Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer

NCT01051362 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: PLD and Carboplatin

Sponsor

The First Affiliated Hospital of Guangzhou Medical University